SecBot SecBot

STAA

STAAR SURGICAL CO
Nasdaq· Ophthalmic Goods· Inc. DE· CIK 0000718937 Healthcare & Medical Devices
$23.23 +0.62 (+2.74%)
Oct 26 4:00 PM ET · prev $22.61
Market cap
$1.1B
Small cap
Consensus
Buy
50% Buy or better · 18 analysts
Median target
$27.00
+16% · range $19.00–37.00
Next earnings
Nov 4
in 8 days · EPS est. $0.17
1 year
−16.4%
from $27.78 · Oct 27
30 days
+11.3%
from $20.87
52-week range
$16.10–33.34
−30% from high · low Feb 13
Avg volume 20D
649.6K
Sep 29 spike 1.66M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · since May 15
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 4, 2026
Strongest NEUTRAL STAAR Surgical reported Q2 2026 net sales of $93.5M (+111% YoY) and GAAP EPS of $0.16, swinging from a net…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since May 15. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 22 added (1 new), 13 trimmed or exited. Largest new: Norges Bank $10.5M.

  • AnalystsBULLISH

    9 of 18 rate it Buy or better. Median target $27.00 (+16%).

  • EstimatesFLAT

    Current-quarter EPS estimate $0.169 → $0.169 over 90 days. 0 up, 1 down in 30 days.

  • TrendUPTREND

    4% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$10.5M
in new stakes
FundMoveSharesValue
Point72 Asset Management, L.P.DOUBLED2,437,446$69.9M
GOLDMAN SACHS GROUP INCDOUBLED2,150,809$61.7M
NORGES BANKNEW365,200$10.5M
UBS Group AGADD341,183$9.8M
RENAISSANCE TECHNOLOGIES LLCDOUBLED340,400$9.8M
CITADEL ADVISORS LLCNEAR_EXIT233,384$6.7M
Squarepoint Ops LLCTRIM188,292$5.4M
BANK OF AMERICA CORP /DE/DOUBLED183,775$5.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 50% rate it Buy or better
Strong Buy4Buy5Hold8Sell1Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +16%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026Stifel
UPGRADE
UPGRADEBuy
Sep 22, 2026Jefferies
MAINTAIN
MAINTAINBuy
Aug 17, 2026Stifel
MAINTAIN
MAINTAINHold
Aug 13, 2026UBS
MAINTAIN
MAINTAINSell
Aug 13, 2026Jefferies
MAINTAIN
MAINTAINBuy
Aug 13, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · since May 15
DateInsiderTypeValue
Aug 14, 2026
ANDREWS DEBORAH J
Chief Financial Officer & EVP
TAX W/H$69.7K
Aug 14, 2026
ANDREWS DEBORAH J
Chief Financial Officer & EVP
AWARD8,952 sh
Aug 14, 2026
ANDREWS DEBORAH J
Chief Financial Officer & EVP
EXERCISE5,233 sh
Aug 14, 2026
ANDREWS DEBORAH J
Chief Financial Officer & EVP
AWARD4,975 sh
Aug 14, 2026
ANDREWS DEBORAH J
Chief Financial Officer & EVP
AWARD29,159 sh
Aug 14, 2026
Michna Magda
Chief Development Officer
TAX W/H$73.2K
Aug 14, 2026
Michna Magda
Chief Development Officer
EXERCISE5,499 sh
Aug 14, 2026
Michna Magda
Chief Development Officer
TAX W/H$14.6K

Earnings setup

Estimates
Nov 4
reports in 8 days
$0.17
EPS estimate, this quarter
0%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.17$0.06–$0.24+0.6%$78.7M
Next Q$0.09$0.02–$0.16+10.9%$68.4M
Current FY$0.84$0.40–$1.07+10.2%$334.3M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 14, 2026 Insider
ANDREWS DEBORAH J surrendered for taxes 2,662 shares
Chief Financial Officer & EVP @ $26.18 ($69.7K)
Aug 14, 2026 Insider
ANDREWS DEBORAH J was granted 8,952 shares
Chief Financial Officer & EVP
Aug 14, 2026 Insider
ANDREWS DEBORAH J acquired via exercise 5,233 shares
Chief Financial Officer & EVP
Aug 12, 2026 SEC
STAAR Surgical reported Q2 2026 net sales of $93.5M (+111% YoY) and GAAP EPS of $0.16, swinging from a net loss of…
8-K — Impact 5/10
Aug 12, 2026 Earnings calendar
STAA Q2 2026 Earnings Scheduled — 2026-08-12
Aug 6, 2026 SEC
STAAR Surgical appointed Warren Foust as permanent President and CEO (effective August 4, 2026), ending the interim…
8-K — Impact 3/10
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — DOUBLED
2,437,446 shares ($69.9M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
2,150,809 shares ($61.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
STAA Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 12, 2026
Earnings date
STAA Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026
Earnings date
STAA Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
Earnings date
STAA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
Earnings date
STAA Q1 2026 Earnings Scheduled — 2026-05-05
Apr 24, 2026
Short interest
FTD: STAA — 265,060 shares ($6.6M) failed to deliver
Settlement: 20260424, Price: $24.84, FTD Value: $6,584,090.4, STAAR SURGICAL CO

SecBot reports

6 filings · 2 bullish · 1 bearish · 3 neutral
All STAA filing & press-release reports (6)